Abstract
Bacteremia is frequently caused by gram-positive organisms such as Staphylococcus aureus or β hemolytic streptococci. While there is adequate information for the diagnosis and management of these common bacteria, less information is available to address bacteremia that is caused by uncommon bacteria such as Citrobacter. Citrobacter species are gram-negative bacilli that have been noted to cause infections in immune compromised patients. The re-speciation of Citrobacter by its varied genetic composition has produced 11 distinct species. While C. braakii is part of the genome species 6 of the previous Citrobacter freundii complex, there is a lack of definitive research on the subject of Citrobacter bacteremia caused by lesser- known species. We report an unusual case of Citrobacter braakii bacteremia in a patient with multiple comorbidities that presented to the hospital with cellulitis and pleural effusion. Blood cultures grew Citrobacter braakii. Despite good response to antibiotic treatment, the patient’s infection proved to be persistent and he succumbed to the cirrhosis of the liver and subsequent renal failure. Multiple and fatal underlying disease processes seem to worsen the likelihood of recovery from unusual infections. We believe our case report can add to the limited data available for C. braakii.
Keywords: Bacteremia, citrobacter braaki, gram-negative, staphylococcus, gram-positive organisms, antibiotic treatment.
Infectious Disorders - Drug Targets
Title:Citrobacter braakii Bacteremia: Case Report and Review of the Literature
Volume: 17 Issue: 1
Author(s): Michelle Oyeka and Suresh Antony
Affiliation:
Keywords: Bacteremia, citrobacter braaki, gram-negative, staphylococcus, gram-positive organisms, antibiotic treatment.
Abstract: Bacteremia is frequently caused by gram-positive organisms such as Staphylococcus aureus or β hemolytic streptococci. While there is adequate information for the diagnosis and management of these common bacteria, less information is available to address bacteremia that is caused by uncommon bacteria such as Citrobacter. Citrobacter species are gram-negative bacilli that have been noted to cause infections in immune compromised patients. The re-speciation of Citrobacter by its varied genetic composition has produced 11 distinct species. While C. braakii is part of the genome species 6 of the previous Citrobacter freundii complex, there is a lack of definitive research on the subject of Citrobacter bacteremia caused by lesser- known species. We report an unusual case of Citrobacter braakii bacteremia in a patient with multiple comorbidities that presented to the hospital with cellulitis and pleural effusion. Blood cultures grew Citrobacter braakii. Despite good response to antibiotic treatment, the patient’s infection proved to be persistent and he succumbed to the cirrhosis of the liver and subsequent renal failure. Multiple and fatal underlying disease processes seem to worsen the likelihood of recovery from unusual infections. We believe our case report can add to the limited data available for C. braakii.
Export Options
About this article
Cite this article as:
Oyeka Michelle and Antony Suresh, Citrobacter braakii Bacteremia: Case Report and Review of the Literature, Infectious Disorders - Drug Targets 2017; 17 (1) . https://dx.doi.org/10.2174/1871526516666161005155847
DOI https://dx.doi.org/10.2174/1871526516666161005155847 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment
of Pulmonary Embolism
Current Pharmaceutical Design Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Prokaryotic Substrate-Binding Proteins as Targets for Antimicrobial Therapies
Current Drug Targets Preparation, Crystallization and Preliminary X-Ray Analysis of Threonine Synthase from Streptococcus mutans
Protein & Peptide Letters Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Synthesis and Characterisation of Super-Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Minimising <i>Aeromonas hydrophila</i> Load from Freshwater
Current Nanoscience Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Editorial [Hot topic: Infective Endocarditis (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Acethylcholinesterase Inhibition, Antibacterial and Antioxidant Properties of Diaryl Oxalates
Current Enzyme Inhibition Development and Validation of A Stability-Indicating Mekc Method for Determination of Flucloxacillin Sodium in Capsules
Current Analytical Chemistry Secondary Prevention of Ischemic Stroke
Current Drug Targets Genetic Modifications of Icosahedral Plant Virus-based Nanoparticles for Vaccine and Immunotherapy Applications
Current Protein & Peptide Science Toll-Like Receptors in Skin Infections and Inflammatory Diseases
Infectious Disorders - Drug Targets Methylene Blue and Vasoplegia: Who, When, and How?
Mini-Reviews in Medicinal Chemistry Antimicrobial Precious-Metal Nanoparticles and their Use in Novel Materials
Recent Patents on Food, Nutrition & Agriculture Antibacterial Function of the Human Cathelicidin-18 Peptide (LL-37) between Theory and Practice
Protein & Peptide Letters Plant Extracts: Search for New Alternatives to Treat Microbial Diseases
Current Pharmaceutical Biotechnology Antibiotic Dosage Regimens in Respiratory Tract Infections in the Pharmacokinetic/Pharmacodynamic Era
Current Respiratory Medicine Reviews